GSK (LSE: GSK) reported a 3% drop in its first-quarter sales compared to a year ago.
The UK drugmaker’s quarterly revenue came in at £6.95 billion ($8.7 billion), which was nonetheless above the £6.5 billion anticipated by analysts.
"We are very focused on our upcoming launches, including our potential RSV older adult vaccine"Excluding COVID-19 related sales, which came to £1.3 billion in the first quarter of 2022, the group's turnover grew by 10%, which shows how the easing off of the pandemic has impacted GSK’s sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze